JP2022516071A5 - - Google Patents

Info

Publication number
JP2022516071A5
JP2022516071A5 JP2021537082A JP2021537082A JP2022516071A5 JP 2022516071 A5 JP2022516071 A5 JP 2022516071A5 JP 2021537082 A JP2021537082 A JP 2021537082A JP 2021537082 A JP2021537082 A JP 2021537082A JP 2022516071 A5 JP2022516071 A5 JP 2022516071A5
Authority
JP
Japan
Prior art keywords
sequence number
cdr3
cdr2
cdr1
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021537082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516071A (ja
JP7558949B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/068820 external-priority patent/WO2020140084A1/en
Publication of JP2022516071A publication Critical patent/JP2022516071A/ja
Publication of JP2022516071A5 publication Critical patent/JP2022516071A5/ja
Priority to JP2024014900A priority Critical patent/JP7745669B2/ja
Application granted granted Critical
Publication of JP7558949B2 publication Critical patent/JP7558949B2/ja
Priority to JP2025100129A priority patent/JP7854093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021537082A 2018-12-27 2019-12-27 抗ctla-4結合タンパク質およびその使用方法 Active JP7558949B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024014900A JP7745669B2 (ja) 2018-12-27 2024-02-02 抗ctla-4結合タンパク質およびその使用方法
JP2025100129A JP7854093B2 (ja) 2018-12-27 2025-06-16 抗ctla-4結合タンパク質およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785659P 2018-12-27 2018-12-27
US62/785,659 2018-12-27
PCT/US2019/068820 WO2020140084A1 (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024014900A Division JP7745669B2 (ja) 2018-12-27 2024-02-02 抗ctla-4結合タンパク質およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022516071A JP2022516071A (ja) 2022-02-24
JP2022516071A5 true JP2022516071A5 (cg-RX-API-DMAC7.html) 2023-01-10
JP7558949B2 JP7558949B2 (ja) 2024-10-01

Family

ID=71126610

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021537082A Active JP7558949B2 (ja) 2018-12-27 2019-12-27 抗ctla-4結合タンパク質およびその使用方法
JP2024014900A Active JP7745669B2 (ja) 2018-12-27 2024-02-02 抗ctla-4結合タンパク質およびその使用方法
JP2025100129A Active JP7854093B2 (ja) 2018-12-27 2025-06-16 抗ctla-4結合タンパク質およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024014900A Active JP7745669B2 (ja) 2018-12-27 2024-02-02 抗ctla-4結合タンパク質およびその使用方法
JP2025100129A Active JP7854093B2 (ja) 2018-12-27 2025-06-16 抗ctla-4結合タンパク質およびその使用方法

Country Status (12)

Country Link
US (2) US12421311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3902821A4 (cg-RX-API-DMAC7.html)
JP (3) JP7558949B2 (cg-RX-API-DMAC7.html)
KR (2) KR102970393B1 (cg-RX-API-DMAC7.html)
CN (2) CN114008071B (cg-RX-API-DMAC7.html)
AU (2) AU2019413366B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012588A2 (cg-RX-API-DMAC7.html)
CA (2) CA3124961C (cg-RX-API-DMAC7.html)
IL (2) IL284156B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007848A (cg-RX-API-DMAC7.html)
SG (1) SG11202106764YA (cg-RX-API-DMAC7.html)
WO (1) WO2020140084A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7296728B2 (ja) * 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
CN114008071B (zh) 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
US20230265192A1 (en) * 2020-07-02 2023-08-24 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
JP2024502035A (ja) * 2020-12-31 2024-01-17 ノヴァロック バイオセラピューティクス, リミテッド Tnfr2に対する抗体およびそれの使用
AU2022303528A1 (en) * 2021-07-02 2024-01-25 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
MX2024007054A (es) * 2021-12-10 2024-09-04 Merck Sharp & Dohme Llc Aglutinantes de mesotelina humana.
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20110166335A1 (en) 2000-06-30 2011-07-07 Corbin David R Xenorhabdus sp. genome sequences and uses thereof
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
WO2006029219A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
SMT201900242T1 (it) * 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
WO2015092394A1 (en) 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
PL3151921T3 (pl) * 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
CN114014930A (zh) * 2015-02-13 2022-02-08 索伦托药业有限公司 结合ctla4的抗体治疗剂
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
DK3303394T3 (da) * 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
AU2016370648B2 (en) * 2015-12-15 2023-03-09 OncoC4, Inc. Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
MX2019010156A (es) 2017-02-27 2020-01-09 Dragonfly Therapeutics Inc Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2.
IL270743B2 (en) * 2017-05-19 2024-09-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
CN114008071B (zh) 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
AU2020210614A1 (en) 2019-01-21 2021-08-26 Sanofi Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers
US20230265192A1 (en) 2020-07-02 2023-08-24 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof

Similar Documents

Publication Publication Date Title
JP7098629B2 (ja) 抗pd-1モノクローナル抗体、その製造方法及び用途
JP6908722B2 (ja) 抗pd−1抗体及びその使用
CN107353342B (zh) PDGF受体β结合多肽
CN110229232B (zh) 双特异性抗体及其用途
JP7663977B2 (ja) 抗pd―l1抗体およびその用途
JP2020532965A5 (cg-RX-API-DMAC7.html)
JP2021508469A5 (cg-RX-API-DMAC7.html)
CN116396386A (zh) Cd3抗体及其药物用途
JP2018531219A6 (ja) Pd−l1抗体
JP2018531219A (ja) Pd−l1抗体
JP2009525764A5 (cg-RX-API-DMAC7.html)
JP2018527919A5 (cg-RX-API-DMAC7.html)
MX2010013239A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
JP2020537520A (ja) Cd137を標的とする抗体とその利用方法
JP2018510617A5 (cg-RX-API-DMAC7.html)
KR20180054590A (ko) 항글리피칸-3 항체 및 이의 응용
TW201829467A (zh) 抗cd3抗體及含有該抗體的分子
JP2025128343A5 (cg-RX-API-DMAC7.html)
JP2010509931A5 (cg-RX-API-DMAC7.html)
JP2024541680A5 (cg-RX-API-DMAC7.html)
CN117024592B (zh) 抗b7h3抗体及其用途
JPWO2020059847A5 (cg-RX-API-DMAC7.html)
KR20230132544A (ko) 신규한 항-그렘린1 항체
JP2020533965A5 (cg-RX-API-DMAC7.html)
JP2021517459A5 (cg-RX-API-DMAC7.html)